演題抄録

口演

開催概要
開催回
第58回・2020年・京都
 

転移性腎細胞癌患者におけるニボルマブとイピリムマブの併用療法の有効性と安全性

演題番号 : O35-4

[筆頭演者]
城戸 宏一:1 
[共同演者]
畠山 真吾:1、田中 壽和:1、野呂 大輔:1、細越 正吾:1、石橋 祐介:1、得居 範子:1、岡本 哲平:1、山本 勇人:1、米山 高弘:1、橋本 安弘:1、伊藤 弘之:2、成田 拓磨:1、川口 俊明:3、大山 力:1

1:弘前大学、2:青森労災病院、3:青森県立中央病院

 

Objectives To investigate the efficacy and safety of nivolumab combined with ipilimumab in patients treated with metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively evaluated 52 patients with mRCC who were treated with nivolumab plus ipilimumab as the first-line therapy between August 2015 and January 2020. Data on patient characteristics, treatment parameters, and adverse events were obtained. Oncological outcomes were stratified according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model. Furthermore, we compared the difference in treatment parameters between the patients with objective response (responders) and nonresponders. Results The median age and follow-up periods were 69 years and 8.2 months, respectively. The one-year progression-free survival and overall survival rates were 55% and 75%, respectively. The objective response rate was 39%; there was a significant difference between the IMDC intermediate- and poor-risk groups (52% vs. 24%). We observed 32(62%) any immune-related adverse events (irAEs) and 16 (31%) severe irAEs (grades III-V). The IMDC poor-risk group and higher value of initial C-reactive protein (≥1.0 mg/dL) were significantly associated with nonresponders. Patients with two factors (the IMDC poor-risk group plus CRP ≥1.0 mg/dL) had a significantly poor overall survival than those with none or single factor. Conclusion Responses to the nivolumab plus ipilimumab were comparable with those in the clinical trial. The incident of treatment-related adverse events was lower than the clinical trial. The IMDC poor-risk group and initial CRP value might have a prognostic value for poor survival.

キーワード

臓器別:腎・尿路・膀胱

手法別:免疫療法

前へ戻る